

Genetic characterization and mutational profiling of foramen magnum meningiomas: a multi-institutional study

Lingyang Hua, MD, PhD,¹ Majd Alkhatib, MD,² Shingo Fujio, MD, PhD,³ Boshr Alhasan, MD,² Sylvia Herold, PhD,^{4,5} Silke Zeugner,^{4,5} Amir Zolal, MD, PhD,² Mido M. Hijazi, MD,² Victoria E. Clark, MD, PhD,⁶ Hiroaki Wakimoto, MD, PhD,⁶ Ganesh M. Shankar, MD, PhD,⁶ Priscilla K. Brastianos, MD,⁷ Frederick G. Barker II, MD,⁶ Daniel P. Cahill, MD, PhD,⁶ Leihao Ren, MD,¹ Ilker Y. Eyūpoglu, MD,² Ye Gong, MD,¹ Gabriele Schackert, MD,² and Tareq A. Juratli, MD^{2,6,8}

¹Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China; ²Department of Neurosurgery, Division of Neuro-Oncology, Faculty of Medicine and Carl Gustav Carus University Hospital, Technische Universität Dresden, Germany; ³Department of Neurosurgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan; ⁴Department of Pathology, Carl Gustav Carus University Hospital, Technische Universität Dresden, Germany; ⁵Core Unit for Molecular Tumor Diagnostics (CMTD), National Center for Tumor Diseases (NCT/UCC), Dresden, Germany; ⁵Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; ³Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts; and ⁵National Center for Tumor Diseases (NCT), Dresden, Germany

OBJECTIVE Foramen magnum (FM) meningiomas pose significant surgical challenges and have high morbidity and mortality rates. This study aimed to investigate the distribution of clinically actionable mutations in FM meningiomas and identify clinical characteristics associated with specific mutational profiles.

METHODS The authors conducted targeted next-generation sequencing of 62 FM meningiomas from three international institutions, covering all relevant meningioma genes (AKT1, KLF4, NF2, POLR2A, PIK3CA, SMO, TERT promoter, and TRAF7). Patients with a radiation-induced meningioma or neurofibromatosis type 2 (NF2) were excluded from the study. Additionally, patient and tumor characteristics, including age, sex, radiological features, and tumor location, were retrospectively collected and evaluated.

CONCLUSIONS These findings provide important insights into the molecular genetics and clinicopathological characteristics of FM meningiomas. The identification of specific genetic alterations associated with tumor location, volume, calcification, histology, and sex at diagnosis may have implications for personalized treatment strategies in the future. https://theins.org/doi/abs/10.3171/2023.11.JNS231936

KEYWORDS foramen magnum; meningioma; skull base; AKT1; NF2; POLR2A; TRAF7; oncology

PORAMEN magnum (FM) meningiomas are rare tumors that present formidable surgical challenges and carry the risk of postoperative complications because of their proximity to critical neurovascular structures.^{1,2} Consequently, FM meningiomas are associated with a higher incidence of morbidity and mortality compared with meningiomas occurring in other locations.^{2,3} Given these factors, it is crucial to delve deeper into the

ABBREVIATIONS FFPE = formalin-fixed paraffin-embedded; FM = foramen magnum; NF2 = neurofibromatosis type 2; NGS = next-generation sequencing. SUBMITTED August 23, 2023. ACCEPTED November 13, 2023. INCLUDE WHEN CITING Published online January 26, 2024; DOI: 10.3171/2023.11.JINS231936.